Isavuconazole
Authors:
- 4 May 2015
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 49 (7) , 825-842
Abstract
Objective: To review the pharmacology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of isavuconazole, a triazole antifungal agent. Data Sources: Studies and reviews were identified through an English language MEDLINE search (1978 to March 2015) and from http://www.clinicaltrials.gov, Food and Drug Administration (FDA) briefing documents, program abstracts from international symposia, and the manufacturer’s Web site. Study Selection and Data Extraction: All published and unpublished trials, abstracts, in vitro and preclinical studies, and FDA briefing documents were reviewed. Data Synthesis: Isavuconazole has activity against a number of clinically important yeasts and molds, including Candida spp, Aspergillus spp, Cryptococcus neoformans, and Trichosporon spp and variable activity against the Mucorales. Isavuconazole, available for both oral and intravenous administration, is characterized by slow elimination allowing once-daily dosing, extensive tissue distribution, and high (>99%) protein binding. The most commonly reported adverse events, which are mild and limited in nature, include nausea, diarrhea, and elevated liver function tests. Its drug interaction potential appears to be similar to other azole antifungals but less than those observed with voriconazole. Comparative trials are under way or have been recently completed for the treatment of candidemia, invasive candidiasis and aspergillosis, and rare mold infections. Conclusions: Isavuconazole has a broad spectrum of activity and favorable pharmacokinetic properties, providing an advantage over other currently available broad-spectrum azole antifungals and a clinically useful alternative to voriconazole for the treatment of invasive aspergillosis. It may also prove useful for the treatment of candidemia and invasive mold infections; however, these indications await the results of clinical trials.Keywords
This publication has 75 references indexed in Scilit:
- Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- The Evolving Role of Antifungal Susceptibility TestingPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory ConcentrationsClinical Infectious Diseases, 2013
- Newer antifungal agentsCurrent Opinion in Pediatrics, 2013
- Current Concepts in Antifungal PharmacologyMayo Clinic Proceedings, 2011
- In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.Journal of Antimicrobial Chemotherapy, 2005
- Antifungal Agents: In Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination TherapyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997Clinical Infectious Diseases, 2001